Memorial Sloan Kettering Cancer Center

GSK's Jemperli (dostarlimab) received FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer, showing a 100% clinical complete response in a phase II trial. The designation aims to expedite development and review of drugs potentially improving serious condition treatments. Jemperli, a PD-1 blocking antibody, is part of GSK's immuno-oncology research.

CLEAR biomarker analyses show Lenvatinib + Pembrolizumab (L+P) significantly improved efficacy over Sunitinib in advanced RCC. No associations found between PD-L1 levels, gene-signature scores, or molecular subtypes with PFS for L+P. Sunitinib showed shorter PFS with high proliferation and MYC signature scores, longer with high angiogenesis scores. Six new molecular subtypes defined, with no association to PFS for either treatment.

FDA granted Breakthrough Therapy Designation to GSK's Jemperli for locally advanced dMMR/MSI-H rectal cancer, based on a Phase II study showing 100% clinical complete response. Jemperli, a PD-1 blocking antibody, demonstrated potential as a monotherapy and in combination with other therapies, with sustained cCR in 24 patients. The trial continues with GSK's AZUR-1 study.

FDA grants breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, marking its second regulatory designation in this population. Dostarlimab, a PD-1-blocking antibody, shows potential alone and in combination with standard care, with a 100% clinical complete response rate in a phase 2 study.

GSK's Jemperli (dostarlimab) received FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer, based on 100% clinical complete response in 42 patients. This follows Fast Track designation in 2023. The designation aims to expedite development of drugs showing substantial improvement over current therapies, which can have significant negative quality-of-life effects.

FDA grants Breakthrough Therapy Designation to GSK's dostarlimab for locally advanced dMMR/MSI-H rectal cancer, based on 100% clinical complete response in 42 patients. Current standard of care involves surgery and chemoradiotherapy with significant quality-of-life impacts.

GSK's Jemperli (dostarlimab) received FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer, based on a 100% clinical complete response rate in a phase II trial. Dostarlimab, a PD-1-blocking antibody, could change treatment for these patients, offering an alternative to current chemotherapy, radiation, and surgery.

A machine learning model integrating clinical and genomic factors outperformed models based solely on clinical or genomic data in predicting outcomes for HR-positive, HER2-negative metastatic breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy, according to results presented at SABCS 2024. The multimodal model identified four risk groups with significantly different progression-free survival rates, indicating superior patient stratification compared to single-factor models. Key predictors included TP53 loss, MYC amplifications, and liver metastasis, among others.

Bizengri (zenocutuzumab-zbco) is the first FDA-approved treatment for advanced pancreatic cancer and NSCLC with NRG1 gene fusion. It targets HER2 and HER3 receptors to block tumor growth signals. Approved under accelerated approval, its continued availability depends on further trials. Clinical data showed response rates of 40% for pancreatic cancer and 33% for NSCLC. Common side effects include diarrhea, muscle pain, and nausea. Bizengri is marketed in the U.S. by Partner Therapeutics under a partnership with Merus.

The Cancer History Project, launched in 2021, aims to preserve oncology's history, exploring milestones like EGFR mutations in lung cancer and the 1964 Surgeon General's Report on Smoking and Health. The project, supported by The Cancer Letter, features multimedia series, podcasts, and institutional histories, attracting growing readership.